Department of Pharmacology Archives
Three Vanderbilt faculty elected to the National Academy of Medicine
Oct. 17, 2022—Three Vanderbilt University faculty members have been elected this year to membership in the National Academy of Medicine, a prestigious, non-governmental organization that advises the nation and the world on important aspects of medical science, health care and public health.
Nanoparticles boost anti-cancer immunity
Aug. 16, 2022—An ingenious targeted nanoparticle approach developed by Vanderbilt researchers reduced tumor burden in a model of ovarian cancer.
Melanoma treatment response
Feb. 24, 2022—Targeting the interaction between melanoma and immune cells could improve responses to targeted cancer therapies, Vanderbilt researchers found.
VUMC researchers find clue to drug-induced arrhythmias
Feb. 24, 2022—Vanderbilt University Medical Center researchers have made a fundamental discovery about how the heart compensates for genetic variations that otherwise could trigger abnormal and potentially fatal heart rhythms.
Seven from VUMC among most highly cited researchers
Nov. 18, 2021—Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
Marnett stepping down as dean of VUSM Basic Sciences
Oct. 12, 2021—Lawrence Marnett, PhD, who has served as dean of Vanderbilt University’s School of Medicine Basic Sciences since its creation in 2016, will step down as dean effective June 30, 2022.
Potential protection from atherosclerosis
Aug. 19, 2021—Vanderbilt researchers have discovered a potential way to reduce atherosclerosis: blocking the modification of an HDL-associated enzyme by reactive molecules called isolevuglandins.
American Heart Association honors Biaggioni’s research
Aug. 5, 2021—Italo Biaggioni, MD, professor of Medicine and Pharmacology, has been selected as a Distinguished Scientist of the American Heart Association for his contributions to cardiovascular and stroke research.
Nature’s “recycler” could reduce heart disease risk: study
Jul. 8, 2021—Researchers at Vanderbilt University Medical Center have identified potential new targets for the prevention of atherosclerosis through the enhancement of autophagy, a natural process for recycling damaged cellular material.
Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma
Jul. 1, 2021—A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.
Personalized Structural Biology aids cancer treatment decisions
Apr. 8, 2021—Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.
NIH grant bolsters research on heart disease, cholesterol
Jan. 21, 2021—Thanks to major funding from the National Institutes of Health (NIH), researchers at Vanderbilt University Medical Center have made major inroads in understanding how high-density lipoprotein (HDL), commonly known as good cholesterol, in some cases may actually contribute to the development of atherosclerosis.
